Matching Adjusted Indirect Comparison (MAIC) Analysis for Ponatinib vs Bosutinib in Third-Line Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.09.1328
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Cost-Utility Analysis of Bosutinib for Previously Treated Chronic Myeloid Leukemia (Cml) in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Alternative Weighting Approaches for Matching Adjusted Indirect Comparisons (Maic)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Prm239 - Does Matching Adjusted Indirect Comparison (Maic) Work? Results From a Simulation Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Role of Bosutinib in the Treatment of Chronic Myeloid Leukemia

Future Oncology
MedicineCancer ResearchOncology
2020English

PSY12 the Cost of Treating Chronic Myeloid Leukemia (CML) in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Comparative Efficacy and Tolerability of Front-Line Treatments for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: An Update Network Meta-Analysis

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Management of Chronic Myeloid Leukemia in Advanced Phase

Frontiers in Oncology
Cancer ResearchOncology
2019English

Cost-Effectiveness of Ponatinib in the Treatment of Patients With Accelerated or Blast Phase - Chronic Myeloid Leukemia in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Bosutinib in the Management of Chronic Myelogenous Leukemia

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy